Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10299117 | 0.89 | RAB9A (0.49) | RAB9AMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL10008639 | 0.88 | MAPT (0.56) | RAB9AMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL10007553 | 0.83 | USP2 (0.51) | RAB9AMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL10008445 | 0.78 | ALDH1A1 (0.52) | RAB9AMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL10299124 | 0.77 | MAPT (0.56) | RAB9AMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL10008805 | 0.77 | ADORA3 (0.59) | RAB9AMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL10008854 | 0.76 | MMP1 (0.55) | RAB9AMEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL10008857 | 0.76 | MMP1 (0.55) | RAB9AMEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL10299504 | 0.76 | MMP1 (0.55) | RAB9AMEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL10008750 | 0.74 | HCAR2 (0.58) | RAB9AALDH1A1SMN1; SMN2GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012092471-A2 | NOVEL TUBULIN INHIBITORS AND METHODS OF USING THE SAME | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2012-07-05 | — | — | WO | claimed |
| US-20120172374-A1 | NOVEL TUBULIN INHIBITORS AND METHODS OF USING THE SAME | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2012-07-05 | — | — | US | claimed |
| US-8883793-B2 | Tubulin inhibitors and methods of using the same | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2014-11-11 | — | — | US | disclosed |
| US-8883793-B2 | Tubulin inhibitors and methods of using the same | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2014-11-11 | — | — | US | disclosed |
| US-20120172374-A1 | NOVEL TUBULIN INHIBITORS AND METHODS OF USING THE SAME | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2012-07-05 | — | — | US | disclosed |
| US-20120172374-A1 | NOVEL TUBULIN INHIBITORS AND METHODS OF USING THE SAME | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2012-07-05 | — | — | US | disclosed |
| WO-2012092471-A2 | NOVEL TUBULIN INHIBITORS AND METHODS OF USING THE SAME | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2012-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172374-A1 | NOVEL TUBULIN INHIBITORS AND METHODS OF USING THE SAME | TUBB1, TUBA1C, TUBB | RAB9A 1099/4885MEN1 740/4885KMT2A 1778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.